Ustekinumab

證據等級: L5

預測適應症: 10 個

Ustekinumab: From Psoriasis to Dermatitis (Atopic Dermatitis)

One-Sentence Summary

Ustekinumab is a human monoclonal antibody targeting IL-12/IL-23, established for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The TxGNN model predicts it may also be effective for Dermatitis (predominantly evidenced as atopic dermatitis), with 7 clinical trials and 20 publications currently supporting this direction, though a blocking gap in official safety labelling remains unresolved.

Quick Overview

Item	Content
Original Indication	Plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (per literature evidence, PMID 36208443; no official Finland licence record on file)
Predicted New Indication	Dermatitis (Atopic Dermatitis)
TxGNN Prediction Score	99.99%
Evidence Level	L2
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, no official DrugBank/TFDA mechanism-of-action record is available for ustekinumab in this evidence pack. However, literature within the pack (PMID 27304428, 36208443) confirms it is a human IgG1 monoclonal antibody targeting the shared p40 subunit of interleukin (IL)-12 and IL-23, which suppresses Th1, Th17, and Th22 lymphocyte activation. On this basis, ustekinumab (brand name Stelara) is indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Psoriasis and atopic dermatitis are both chronic immune-mediated inflammatory skin diseases, though they are traditionally driven by different T-helper axes — psoriasis by Th17/Th22, and atopic dermatitis primarily by Th2 with a variable Th22 contribution. Because ustekinumab blocks the IL-12/23 axis shared upstream of Th17 and Th22 differentiation, there is a plausible mechanistic bridge between the two conditions.

This bridge is not purely theoretical: PMID 27745907 directly demonstrates that ustekinumab down-regulates Th2/Th22 gene expression in patients with severe atopic dermatitis, supporting biological applicability. Multiple Phase 2 RCTs (NCT01945086, NCT01806662) and a body of systematic reviews and real-world studies have since tested this hypothesis directly in atopic dermatitis patients, which is the primary reason the evidence level here exceeds a pure prediction-only score.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01945086	Phase 2	Completed	79	Randomized, double-blind, placebo-controlled trial of ustekinumab in adult Japanese patients with severe atopic dermatitis
NCT01806662	Phase 2	Completed	32	Randomized pilot study of ustekinumab in chronic atopic dermatitis with sub-optimal response to prior therapy
NCT02074982	Phase 3	Completed	676	CLEAR study: secukinumab vs. ustekinumab efficacy (PASI-75 at week 16) in moderate-to-severe plaque psoriasis; long-term safety and tolerability also assessed
NCT05535738	Phase 2/3	Recruiting	45	Suction-blistering contact dermatitis model to study skin inflammation mechanisms of biologic therapies
NCT07041112	N/A	Completed	1000	Retrospective pharmacogenetic cohort evaluating 10-year survival of biologic therapies in cutaneous psoriasis/psoriatic arthritis
NCT01356758	N/A	Completed	126	Cardiovascular risk assessment in patients with severe psoriasis treated with biologic agents
NCT07352566	Phase 4	Not yet recruiting	10	Microdevice delivering FDA-approved atopic dermatitis/psoriasis drugs directly into skin for comparative in-situ testing

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27304428	2017	RCT	Experimental Dermatology	Phase 2 double-blind, placebo-controlled trial (n=33) of ustekinumab in moderate-to-severe atopic dermatitis
28338223	2017	RCT	British Journal of Dermatology	Randomized, double-blind, placebo-controlled Phase 2 study of ustekinumab in Japanese patients with severe atopic dermatitis
33074565	2021	Systematic Review	Allergy	Systematic review/meta-analysis of systemic treatments for moderate-to-severe atopic dermatitis, informing EAACI guidelines
29164954	2018	Systematic Review	J Dermatological Treatment	Systematic review of efficacy and safety of ustekinumab specifically in atopic dermatitis
29098604	2018	Systematic Review	Am J Clinical Dermatology	Systematic review/meta-analysis assessing efficacy of biologics, including ustekinumab, in atopic dermatitis
33849369	2022	Observational	J Dermatological Treatment	Real-world evidence analysis of ustekinumab effectiveness in atopic dermatitis patients
27745907	2017	Clinical/Mechanistic Study	J American Academy of Dermatology	Ustekinumab treatment in severe atopic dermatitis showed down-regulation of Th2/Th22 gene expression
36208443	2022	Review	Dermatologic Therapy	Review of off-label uses of ustekinumab, synthesizing trials, observational studies, and case reports across indications
30850043	2019	Review	Dermatologic Clinics	Review of emerging treatment developments in atopic dermatitis, including biologics beyond dupilumab
37929636	2024	Case Report	Australasian J Dermatology	Case of combined dupilumab + ustekinumab therapy in a patient with severe atopic dermatitis and Crohn's disease

Finland Market Information

Ustekinumab is currently not marketed in Finland — no Fimea marketing authorizations are on file (0 licences recorded).

Safety Considerations

Please refer to the package insert for safety information. (Note: official TFDA/Fimea package-insert warnings, contraindications, and DDI data are currently a blocking data gap — see Conclusion.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale:

Two completed Phase 2 RCTs, a Th2/Th22 mechanistic study, and multiple systematic reviews/real-world evidence directly support ustekinumab's efficacy in atopic dermatitis, giving reasonable (L2) confidence in the repurposing hypothesis. However, the drug is not currently marketed in Finland and official safety labelling (warnings/contraindications) is a Blocking data gap that prevents entry into formal S1 safety evaluation.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) to resolve the blocking safety data gap (DG001)
Confirmed DrugBank mechanism-of-action record (DG002)
A completed Phase 3 RCT specifically in atopic dermatitis (current strongest direct evidence is Phase 2)
Finland market authorization/registration pathway assessment, since the product currently holds no local licence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.